{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:07:50Z","timestamp":1782544070058,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"name":"Ms Vasugi Sanjayan (Allori Pty Ltd., Australia)"},{"name":"Dr Anja Becher (Sydney, Australia)"},{"name":"Amgen Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clin Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1111\/ajco.12517","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T15:09:20Z","timestamp":1479308960000},"page":"266-276","source":"Crossref","is-referenced-by-count":58,"title":["Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures"],"prefix":"10.1111","volume":"13","author":[{"given":"Kenneth","family":"Pittman","sequence":"first","affiliation":[{"name":"The Queen Elizabeth Hospital; South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoland C","family":"Antill","sequence":"additional","affiliation":[{"name":"Cabrini Institute, Cabrini Health, and Department of Oncology; Frankston Hospital; Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Goldrick","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology; Amgen Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Goh","sequence":"additional","affiliation":[{"name":"Royal Brisbane & Women's Hospital; Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"de Boer","sequence":"additional","affiliation":[{"name":"Royal Melbourne and Epworth Hospitals; Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"10.1111\/ajco.12517-BIB0001|ajco12517-cit-0001","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1111\/ajco.12517-BIB0002|ajco12517-cit-0002","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00520-013-1755-1","article-title":"Reducing the burden of bone metastases: current concepts and treatment options","volume":"21","author":"Moos","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1111\/ajco.12517-BIB0003|ajco12517-cit-0003","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/ajco.12517-BIB0004|ajco12517-cit-0004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1111\/ajco.12517-BIB0005|ajco12517-cit-0005","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1111\/ajco.12517-BIB0006|ajco12517-cit-0006","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1111\/ajco.12517-BIB0007|ajco12517-cit-0007","first-page":"89","article-title":"Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors","volume":"6","author":"Brown-Glaberman","year":"2012","journal-title":"Biologics"},{"key":"10.1111\/ajco.12517-BIB0008|ajco12517-cit-0008","unstructured":"Amgen 2011"},{"key":"10.1111\/ajco.12517-BIB0009|ajco12517-cit-0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1111\/ajco.12517-BIB0010|ajco12517-cit-0010","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12517-BIB0011|ajco12517-cit-0011","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12517-BIB0012|ajco12517-cit-0012","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","article-title":"Denosumab dose selection for patients with bone metastases from solid tumors","volume":"18","author":"Doshi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ajco.12517-BIB0013|ajco12517-cit-0013","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1111\/ajco.12517-BIB0014|ajco12517-cit-0014","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/ajco.12517-BIB0015|ajco12517-cit-0015","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12517-BIB0016|ajco12517-cit-0016","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/ajco.12517-BIB0017|ajco12517-cit-0017","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1111\/ajco.12517-BIB0018|ajco12517-cit-0018","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1111\/ajco.12517-BIB0019|ajco12517-cit-0019","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1111\/ajco.12517-BIB0020|ajco12517-cit-0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","article-title":"The clinical approach toward giant cell tumor of bone","author":"der Heijden","year":"2014","journal-title":"Oncologist"},{"key":"10.1111\/ajco.12517-BIB0021|ajco12517-cit-0021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1111\/ajco.12517-BIB0022|ajco12517-cit-0022","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/bmj.39582.589433.BE","article-title":"Diagnosis and management of hypocalcaemia","volume":"336","author":"Cooper","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/ajco.12517-BIB0023|ajco12517-cit-0023","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/SPC.0b013e3283640f5f","article-title":"Managing hypercalcaemia and hypocalcaemia in cancer patients","volume":"7","author":"Fallah-Rad","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1111\/ajco.12517-BIB0024|ajco12517-cit-0024","unstructured":"Cancer Therapy Evaluation Program 2006"},{"key":"10.1111\/ajco.12517-BIB0025|ajco12517-cit-0025","doi-asserted-by":"crossref","unstructured":"Cancer Therapy Evaluation Program 2009","DOI":"10.1016\/S1040-1741(09)79361-3"},{"key":"10.1111\/ajco.12517-BIB0026|ajco12517-cit-0026","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1111\/ajco.12517-BIB0027|ajco12517-cit-0027","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/1060028014539919","article-title":"Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer","volume":"48","author":"Ikesue","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ajco.12517-BIB0028|ajco12517-cit-0028","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","article-title":"Identification of the risk factors associated with hypocalcemia induced by denosumab","volume":"36","author":"Okada","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1111\/ajco.12517-BIB0029|ajco12517-cit-0029","unstructured":"eviQ 2014"},{"key":"10.1111\/ajco.12517-BIB0030|ajco12517-cit-0030","unstructured":"eviQ 2015"},{"key":"10.1111\/ajco.12517-BIB0031|ajco12517-cit-0031","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon.13.211","article-title":"Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents","volume":"10","author":"Campisi","year":"2014","journal-title":"Future Oncol"},{"key":"10.1111\/ajco.12517-BIB0032|ajco12517-cit-0032","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1111\/j.1834-7819.2005.tb00384.x","article-title":"The dental implications of bisphosphonates and bone disease","volume":"50","author":"Cheng","year":"2005","journal-title":"Aust Dent J"},{"key":"10.1111\/ajco.12517-BIB0033|ajco12517-cit-0033","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1601-0825.2012.01903.x","article-title":"Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"18","author":"Bedogni","year":"2012","journal-title":"Oral Dis"},{"key":"10.1111\/ajco.12517-BIB0034|ajco12517-cit-0034","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.oraloncology.2013.06.008","article-title":"Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals","volume":"49","author":"Hinchy","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1111\/ajco.12517-BIB0035|ajco12517-cit-0035","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1111\/ajco.12517-BIB0036|ajco12517-cit-0036","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/ajco.12517-BIB0037|ajco12517-cit-0037","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1111\/ajco.12517-BIB0038|ajco12517-cit-0038","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1111\/ajco.12517-BIB0039|ajco12517-cit-0039","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jbiomech.2015.01.032","article-title":"American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures","volume":"48","author":"Geissler","year":"2015","journal-title":"J Biomech"},{"key":"10.1111\/ajco.12517-BIB0040|ajco12517-cit-0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bone.2013.07.012","article-title":"Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report","volume":"56","author":"Bissonnette","year":"2013","journal-title":"Bone"},{"key":"10.1111\/ajco.12517-BIB0041|ajco12517-cit-0041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bone.2015.06.017","article-title":"Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone","volume":"81","author":"Lim","year":"2015","journal-title":"Bone"},{"key":"10.1111\/ajco.12517-BIB0042|ajco12517-cit-0042","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1111\/ajco.12517-BIB0043|ajco12517-cit-0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1111\/ajco.12517-BIB0044|ajco12517-cit-0044","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2014-1375","article-title":"Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts","volume":"99","author":"Pazianas","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/ajco.12517-BIB0045|ajco12517-cit-0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/17453674.2013.859423","article-title":"Denosumab and atypical femoral fractures","volume":"85","author":"Aspenberg","year":"2014","journal-title":"Acta Orthop"},{"key":"10.1111\/ajco.12517-BIB0046|ajco12517-cit-0046","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/17453674.2013.854668","article-title":"Atypical femoral fractures bilaterally in a patient receiving denosumab","volume":"85","author":"Drampalos","year":"2014","journal-title":"Acta Orthop"},{"key":"10.1111\/ajco.12517-BIB0047|ajco12517-cit-0047","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical fracture of the femur in a patient using denosumab-a case report","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthop"},{"key":"10.1111\/ajco.12517-BIB0048|ajco12517-cit-0048","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1111\/ajco.12517-BIB0049|ajco12517-cit-0049","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang","year":"2015","journal-title":"Oncologist"},{"key":"10.1111\/ajco.12517-BIB0050|ajco12517-cit-0050","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12517","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajco.12517\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T07:46:56Z","timestamp":1625298416000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12517"}},"subtitle":["Denosumab: rare toxicities"],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1111\/ajco.12517","archive":["Portico"],"relation":{},"ISSN":["1743-7555"],"issn-type":[{"value":"1743-7555","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}